IMP 4297

Drug Profile

IMP 4297

Alternative Names: IMP 4297; IMPO4297

Latest Information Update: 08 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator IMPACT Therapeutics
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Poly(ADP-ribose) polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 03 May 2017 Phase-I clinical trials in Solid tumours in China (PO) prior to May 2017
  • 10 Apr 2017 IMPACT Therapeutics plans a phase Ib trial in Australia/China for Solid tumours
  • 30 Mar 2017 IMPACT Therapeutics plans a phase II/III trial in Breast, ovarian, or prostate cancer (IMPACT Therapeutics website, March 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top